JP Morgan Chase’s Renalytix plc American Depositary Shares RNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1
Closed 7892
2024
Q3
$0 Sell
1
-16,164
-100% -$5.17K ﹤0.01% 7762
2024
Q2
$3.73K Sell
16,165
-25,831
-62% -$15.4K ﹤0.01% 6433
2024
Q1
$34.9K Sell
41,996
-6,333
-13% -$4.34K ﹤0.01% 6069
2023
Q4
$18.8K Sell
48,329
-21,660
-31% -$17.3K ﹤0.01% 6263
2023
Q3
$112K Sell
69,989
-5,134
-7% -$14.2K ﹤0.01% 5406
2023
Q2
$219K Sell
75,123
-5,790
-7% -$13.1K ﹤0.01% 5021
2023
Q1
$196K Sell
80,913
-1,255
-2% -$3.48K ﹤0.01% 5082
2022
Q4
$153K Sell
82,168
-3,905
-5% -$6.1K ﹤0.01% 5169
2022
Q3
$110K Sell
86,073
-2,337
-3% -$5.09K ﹤0.01% 5246
2022
Q2
$218K Buy
88,410
+43,724
+98% +$208K ﹤0.01% 5032
2022
Q1
$309K Buy
44,686
+13,782
+45% +$146K ﹤0.01% 4967
2021
Q4
$492K Buy
30,904
+24,740
+401% +$495K ﹤0.01% 4840
2021
Q3
$124K Buy
6,164
+203
+3% +$5.24K ﹤0.01% 5467
2021
Q2
$184K Sell
5,961
-1,670
-22% -$50K ﹤0.01% 5291
2021
Q1
$196K Buy
+7,631
New +$191K ﹤0.01% 5157

Other funds holding RNLX

JP Morgan Chase's RNLX Position: Q4 2024 in Review

JP Morgan Chase sold out of Renalytix plc American Depositary Shares (RNLX) in Q4 2024, closing a stake of 1 share.

JP Morgan Chase first reported a position in RNLX in Q1 2021 and held it in 15 quarters. The position peaked at $492K in Q4 2021. 3 funds tracked by Wall St. Rank hold RNLX as of Q4 2024.

  • JP Morgan Chase reported no remaining Renalytix plc American Depositary Shares position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 1 Renalytix plc American Depositary Shares share in Q4 2024.
  • JP Morgan Chase first reported a position in Renalytix plc American Depositary Shares in Q1 2021 and held it in 15 quarters.
  • JP Morgan Chase's Renalytix plc American Depositary Shares position peaked at $492K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Renalytix plc American Depositary Shares as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.